CPI-169, an indole-based selective EZH2 inhibitor, first showed significant antitumor activity and pharmacodynamic (PD) target engagement in a DLBCL mouse xenograft model of EZH2MUT, but with limited oral bioavailability [192]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.